XAIR Profile
Beyond Air, Inc. is a commercial medical device and biopharmaceutical company dedicated to advancing respiratory care through innovative technologies. The company is focused on the development of its LungFit platform, a cutting-edge nitric oxide generator and delivery system designed to address various respiratory conditions.
The LungFit platform includes several key products. LungFit PH is designed specifically for treating persistent pulmonary hypertension of the newborn (PPHN), a critical condition affecting infants with compromised oxygen delivery. LungFit PRO is under development to address viral lung infections such as community-acquired viral pneumonia, including COVID-19, and bronchiolitis in hospitalized patients. Additionally, LungFit GO aims to provide therapeutic solutions for infections caused by nontuberculous mycobacteria, offering a potential breakthrough in managing these challenging conditions.
Beyond Air’s innovative approach leverages its proprietary technology to improve patient outcomes across various respiratory conditions. The company’s development pipeline reflects a commitment to addressing unmet medical needs through advanced nitric oxide therapy. Its focus extends beyond traditional applications, targeting a range of viral and bacterial infections that have significant clinical impact.
Founded as AIT Therapeutics, Inc., the company rebranded to Beyond Air, Inc. in June 2019 to better reflect its expanded focus on transformative respiratory therapies. Headquartered in Garden City, New York, Beyond Air, Inc. continues to drive forward with its mission to enhance respiratory health through novel and effective medical solutions.
|
